Veru Inc. is an Oncology and Urology Biopharmaceutical Company Developing and Commercializing Novel Medicines for Prostate Cancer and Urology Specialty Pharmaceuticals.

Veru Pipeline May 2020

The Company’s prostate cancer pipeline includes VERU-111, VERU-100, and zuclomiphene citrate. VERU-111 is an oral, next-generation, first-in-class small molecule that targets and disrupts alpha and beta tubulin subunits of microtubules in cells to treat metastatic prostate cancer patients whose disease is resistant to both castration and novel androgen-blocking agents (e.g., abiraterone or enzalutamide)1. VERU-111 is being evaluated in men with metastatic castration and androgen-blocking agent resistant prostate cancer in an open label Phase 1b and phase 2 clinical trial. VERU-111 is also being evaluated in a Phase 2 clinical trial for the treatment of Severe Acute Respiratory Syndrome Coronavirus 2 in patients at high risk for Acute Respiratory Distress Syndrome. VERU-100 is a novel, proprietary peptide formulation for ADT with multiple potential beneficial clinical attributes addressing the shortfalls of current FDA-approved ADT formulations for the treatment of advanced prostate cancer. VERU-100 is a long-acting gonadotropin-releasing hormone (GnRH) antagonist designed to be administered as a small volume subcutaneous 3-month depot injection without a loading dose. VERU-100 will immediately suppress testosterone with no testosterone surge upon initial or repeated administration2—a problem which occurs with currently approved luteinizing hormone-releasing hormone (LHRH) agonists used for ADT. Currently, there are no GnRH antagonists commercially approved beyond a one-month injection. VERU-100 is anticipated to enter a Phase 2 dose-finding study in calendar year 2020. Zuclomiphene citrate is an oral nonsteroidal estrogen receptor agonist used to treat hot flashes, a common side effect caused by androgen deprivation therapy (ADT) in men with advanced prostate cancer. Zuclomiphene citrate is being evaluated in a Phase 2 clinical trial in men with advanced prostate cancer who experience moderate to severe hot flashes.

The Company is also advancing new drug formulations in its specialty pharmaceutical pipeline addressing unmet medical needs in urology such as the Tadalafil and Finasteride Combination (TADFIN®) for the administration of tadalafil 5mg and finasteride 5mg combination formulation dosed daily to treat urinary tract symptoms caused by benign prostatic hyperplasia (BPH). Tadalafil (CIALIS®) is currently approved for treatment of BPH and erectile dysfunction and finasteride is currently approved for treatment of BPH (finasteride 5mg PROSCAR®) and male pattern hair loss (finasteride 1mg PROPECIA®). The co-administration of tadalafil and finasteride has been shown to be more effective for the treatment of BPH than by finasteride alone3. The Company had a successful pre-New Drug Application (NDA) meeting with the FDA and the expected submission of the NDA for TADFIN® is the second half of calendar year 2020. The Company is also developing Tamsulosin XR capsules which is a formulation of tamsulosin, the active ingredient in FLOMAX®, which the Company has designed to avoid the “food effect” inherent in currently marketed versions of the drug4, allowing for potentially safer administration and improved patient compliance.

  1. Getzenberg, et al., “Efficacy of VERU-111, an oral alpha and beta tubulin inhibitor, in taxol responsive and resistant prostate cancer models”, EAU Poster, 2018
  2. Getzenberg, et al., “Determination of the ability of a novel, long-acting subcutaneous GnRH antagonist, VERU-100. to castrate without a testosterone surge in a rat model, GU ASCO Poster, 2020
  3. “Casabe, et al., “”Efficacy and Safety of the Coadministration of Tadalafil Once Daily with Finasteride for 6 Months in Men with Lower
    Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia””, The Journal of Urology, Vol. 191, 727-733, March 2014.”
  4. Flomax Tamsulosin Package Insert
    Casabe, et al., “Efficacy and Safety of the Coadministration of Tadalafil Once Daily with Finasteride for 6 Months in Men with Lower Urinary Tract Symptoms and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia”, The Journal of Urology, Vol. 191, 727-733, March 2014.

CURRENT PIPELINE

VERU-111 Prostate Cancer

VERU-111 Prostate Cancer

A novel oral selective antitubulin that targets alpha and beta tubulin for metastatic prostate cancer as well as for other forms of advanced cancers.

LEARN MORE

VERU-111 COVID-19

VERU-111 COVID-19

Novel Microtubule Depolymerization Drug with Dual Mechanism of Action – Antiviral for SARS-COV-2 & Anti-Inflammatory for Cytokine Storm

LEARN MORE

VERU-100 Prostate Cancer

VERU-100 Prostate Cancer

VERU-100 is a novel, proprietary peptide formulation designed with multiple beneficial clinical attributes addressing the shortfalls of the current multi-billion-dollar androgen deprivation therapy market for advanced prostate cancer.

LEARN MORE

Zuclomiphene citrate

Zuclomiphene citrate

Estrogen receptor agonist for the treatment of hot flashes caused by prostate cancer hormonal therapies in men with advanced prostate cancer.

LEARN MORE

Tadalafil 5mg and Finasteride 5mg combination tablet (TADFIN®)

Tadalafil 5mg and Finasteride 5mg combination tablet (TADFIN®)

TADFIN® combination of a PDE5 inhibitor and 5 alpha reductase inhibitor for the treatment of enlarged prostate (BPH)

LEARN MORE

VERU IS ENROLLING PATIENTS

VERU-111

CLINICAL TRIALS

To Evaluate the Safety and Tolerability of VERU-111 in Men with Advanced Metastatic Castration Resistant Prostate Cancer

GET MORE INFORMATION

VERU-111 and SARS-CoV-2

CLINICAL TRIALS

To Evaluate VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

GET MORE INFORMATION

Zuclomiphene Citrate

CLINICAL TRIALS

To Ameliorate the Vasomotor Symptoms (Hot Flashes) Resulting from Androgen Deprivation Therapy in Men with Advanced Prostate Cancer

GET MORE INFORMATION